newsfilter
← Latest News
GlobeNewswire·

Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Secured